# BRUIN-CLL-313 (NCT05023980)

> A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05023980
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Loxo Oncology, Inc.
- Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
- Interventions: Pirtobrutinib; Bendamustine; Rituximab
- Enrollment: 282
- Primary outcome: Arm A Compared to Arm B: Progression-free Survival (PFS), Assessed by Independent Review Committee (IRC)

## Commentary we found

- YouTube: 36
- Podcasts: 21
- X threads: 20
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=bruin-cll-313-nct05023980

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05023980", "email": "<work email>"}; the inbox owner confirms by the emailed link.